In yesterday’s Wall Street session, Sigilon Therapeutics Inc. (NASDAQ:SGTX) shares traded at $0.55, up 32.95% from the previous session.
As of this writing, 5 analysts cover Sigilon Therapeutics Inc. (NASDAQ:SGTX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $0.50, we find $2.00. Given the previous closing price of $0.41, this indicates a potential upside of 387.8 percent. SGTX stock price is now 38.38% away from the 50-day moving average and -22.63% away from the 200-day moving average. The market capitalization of the company currently stands at $14.21M.
There are 2 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $3.50 as their price target over the next twelve months.
With the price target reduced from $15 to $4, Jefferies Downgraded its rating from Buy to Hold for Sigilon Therapeutics Inc. (NASDAQ: SGTX). On October 29, 2021, BTIG Research recently initiated its ‘Buy’ rating on the stock quoting a target price of $14, while ‘Jefferies’ rates the stock as ‘Buy’.
A total of 13.34% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SGTX stock. A new stake in Sigilon Therapeutics Inc. shares was purchased by MAN GROUP PLC during the first quarter worth $8,000. AMALGAMATED FINANCIAL CORP. invested $1,000 in shares of SGTX during the first quarter. In total, there are 54 active investors with 52.20% ownership of the company’s stock.
Wednesday morning saw Sigilon Therapeutics Inc. (NASDAQ: SGTX) opened at $0.6003. During the past 12 months, Sigilon Therapeutics Inc. has had a low of $0.29 and a high of $2.22. As of last week, the company has a debt-to-equity ratio of 0.46, a current ratio of 2.60, and a quick ratio of 2.60. The fifty day moving average price for SGTX is $0.3968 and a two-hundred day moving average price translates $0.7097 for the stock.
The latest earnings results from Sigilon Therapeutics Inc. (NASDAQ: SGTX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.44, missing analysts’ expectations of -$0.43 by -0.01. This compares to -$0.63 EPS in the same period last year. The company reported revenue of $4.25 million for the quarter, compared to $1.95 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 118.39 percent. For the current quarter, analysts expect SGTX to generate $2.5M in revenue.
Sigilon Therapeutics Inc.(SGTX) Company Profile
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.